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Abstract
Background: Idiopathic and familial forms of pulmonary arterial hypertension (PAH) occur more frequently in
women than men. However, the reason for this remains unknown. Both the calcium binding protein S100A4/Mts1
(Mts1) and its endogenous receptor (receptor for advanced glycosylation end products; RAGE) have been
implicated in the development of PAH. We wished to investigate if the Mts1/RAGE pathway may play a role in the
gender bias associated with PAH.
Methods: We investigated the effects of gender on development of PAH in mice over-expressing Mts1 (Mts1+
mice) via measurement of pulmonary arterial remodeling, systolic right ventricular pressure (sRVP) and right
ventricular hypertrophy (RVH). Gender differences in pulmonary arterial Mts1 and RAGE expression were assessed
by qRT-PCR and immunohistochemistry. Western blotting and cell counts were used to investigate interactions
between 17b-estradiol, Mts1 and RAGE on proliferation of human pulmonary artery smooth muscle cells
(hPASMCs). Statistical analysis was by one-way analysis of variance with Dunnetts post test or two-way analysis of
variance with Bonferronis post test, as appropriate.
Results: Female Mts1+ mice developed increased sRVP and pulmonary vascular remodeling, whereas male Mts1+
mice remained unaffected. The development of plexiform-like lesions in Mts1+ mice was specific to females. These
lesions stained positive for both Mts1 and RAGE in the endothelial and adventitial layers. Expression of pulmonary
arterial Mts1 was greater in female than male Mts1+ mice, and was localised to the medial and adventitial layers in
non plexiform-like pulmonary arteries. RAGE gene expression and immunoreactivity were similar between male and
female Mts1+ mice and RAGE staining was localised to the endothelial layer in non plexiform-like pulmonary
arteries adjacent to airways. In non-plexiform like pulmonary arteries not associated with airways RAGE staining was
present in the medial and adventitial layers. Physiological concentrations of 17b-estradiol increased Mts1 expression
in hPASMCs. 17b-estradiol-induced hPASMC proliferation was inhibited by soluble RAGE, which antagonises the
membrane bound form of RAGE.
Conclusions: Mts1 over-expression combined with female gender is permissive to the development of
experimental PAH in mice. Up-regulation of Mts1 and subsequent activation of RAGE may contribute to 17b-
estradiol-induced proliferation of hPASMCs.
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Pulmonary arterial hypertension (PAH) is a progressive
disease associated with increased constriction and remo-
deling of the pulmonary vasculature. This leads to right
heart failure and mean survival time in PAH patients is
typically less than 3 years. Both idiopathic PAH and
familial PAH occur more frequently in women than
men (>2:1) [1-3]. Despite this, the underlying reason for
the increased prevalence in women remains unclear.
This has been difficult to investigate in animal models
of PAH as male rats are more prone than females to
hypoxia-induced PAH and paradoxically, estrogens pro-
tect against monocrotaline-induced PAH [4,5].
S100A4/Mts1 (Mts1) is a member of the S100 family
of small calcium binding proteins. On interaction with
c a l c i u m ,ac o n f o r m a t i o n a lc h a n g ee x p o s e sah y d r o p h o -
bic domain which can interact with and regulate the
function of target proteins. Mts1 has been implicated in
the pathogenesis of both human and experimental PAH.
For example, Mts1 is up-regulated in the neointima and
adventitia of occlusive and early plexiform lesions in
PAH patients [6]. Moreover, mice over-expressing Mts1
(Mts1+ mice) develop increased right ventricular systolic
pressure (sRVP) [7] and a subset of these mice develop
pulmonary arterial remodeling similar to human plexo-
genic lesions [6]. These lesions are associated with a
heightened activity of elastase and pulmonary artery
elastin degradation [8,9]. Mts1 is synthesized and
released from human pulmonary artery smooth muscle
cells (hPASMCs) in response to serotonin. It can then
act in an autocrine fashion to mediate the proliferation
and migration of hPASMCs via activation of the recep-
tor for advanced glycosylation end products (RAGE)
[10]. The primary defect of familial PAH is a mutation
in the gene encoding bone morphogenetic protein
receptor type 2 (BMPRII) [11] and this is present in at
least 70% of familial PAH cases. Interestingly, RAGE has
also been shown to interact with the BMPRII pathway
in the pulmonary vasculature. The migratory effect of
the BMPRII ligand BMP-2 in hPASMCs can be blocked
by RAGE antagonism and likewise Mts1 induced-migra-
tion can be blocked with BMPRII short interference
RNA showing cross talk between these pathways [12].
Thus increased activation of the Mts1/RAGE pathway
may provide a ‘second hit’ risk factor in patients with a
BMPRII mutation.
17b-estradiol (the predominant circulating estrogen in
females) acts via RAGE to induce post-ischemic leuko-
cyte adhesion in diabetic ovariectomized rats [13].
RAGE has also been hypothesised as important in deter-
mining the severity of breast cancer; the role of estro-
gens in the pathogenesis of breast cancer have
previously been well described [14]. Interactions
between estrogens and Mts1/RAGE remain to be inves-
tigated in the pulmonary circulation.
In this study, we investigated pulmonary vascular
effects of female gender and 17b-estradiol on the Mts1/
RAGE pathway in vivo and in vitro respectively. We
show that female gender is permissive in the develop-
ment of PAH in Mts1+ mice. Unlike their male counter-
parts, female Mts1+ mice develop plexiform-like lesions.
Mts1 gene expression is increased in the lungs of female
Mts1+ mice compared to male Mts1+ mice and this
translates into greater expression of Mts1 protein in the
distal pulmonary arteries. Physiological concentrations
of 17b-estradiol increase Mts1 expression in hPASMCs,
and sRAGE can inhibit 17b-estradiol-induced prolifera-
tion of these cells. This permissive effect of 17b-estra-
diol may contribute to the PAH phenotype observed in
these female Mts1+ mice.
Methods
Animals
The investigation conforms with the United Kingdom
Animal procedures act, 1986 and with the Guide for the
Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH publication No.
85-23, revised 1996).
The S100A4/Mts1 mouse
Mts1+ mice were bred on a CBA x C57BL/6 back-
ground as described previously [15]. Mice were group-
housed under standard laboratory conditions, with tap
water and rat chow available ad libitum,o na1 2h r
light/dark cycle. The PAH phenotype in transgenic mice
is age-dependent and observed most clearly at 5 months
of age. Accordingly, mice were studied at 5 months of
age (25-35 g).
Assessment of PAH indicators
In vivo hemodynamic measurements
Mice were anaesthetised using isofluorane supplemented
with O2 (induction: 3%, maintenance: 1-1.5%). Pressure
measurements were analysed as described previously
[16]. Briefly, systemic arterial pressure was obtained via
a microcannula (Harvard, 0.2 mm ID) inserted into a
carotid artery. A 25-gauge needle was advanced into the
right ventricle by use of a transdiaphragmatic approach
for measurement of RVP. Data was recorded and ana-
lysed using a Biopac MP35 data acquisition system (Bio-
pac Systems Inc, USA). Ten mice per group were
studied.
Lung histology
One sagittal section was obtained from the left lung.
Sections were stained with Elastica-Van Gieson stain
and microscopically assessedi nab l i n d e df a s h i o nf o r
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external diameter) as described previously [16]. Lung
sections from 4-6 mice from each group were studied.
Approximately 150 arteries from each lung section were
assessed.
Measurement of right ventricular hypertrophy
RVH was assessed by measuring the right ventricular
free wall (RV) and left ventricle together with the sep-
tum (LV + S) separately. The ratio RV/LV+S was
calculated.
RNA Preparation and qRT-PCR
Total RNA was isolated using miRNeasy Mini Kit (Qia-
gen) and reverse-transcribed using Taqman reverse tran-
scription kit (Applied Biosystems) according to the
instructions of the manufacturer. Quantitative real-time
PCR was performed using Universal master mix II with
Assays on Demand gene expression probes (system and
probes from Applied Biosystems) for S100A4/Mts1
(assay ID: Mm00803372_g1), RAGE (assay ID:
Mm01134790_g1) and HMGCoA reductase (assay ID:
Mm01282499_m1) using the comparative delta-CT
method with b2-microglobulin as the endogenous con-
trol. GAPDH was used as a further endogenous control
for HMGCoA reductase.
Immunohistochemistry
Paraffin embedded lung sections (5 μmt h i c k )w e r e
mounted on poly-L-lysine slides. Slides were dewaxed
and sections rehydrated by immersion in ethanol (100%,
95%, and 70%) and then in distilled water. After antigen
retrieval, endogenous peroxidase activity was blocked
with 3% H2O2 in methanol for 30 minutes. Sections
were pre-incubated in phosphate buffered saline supple-
mented with 1% bovine serum albumin, 10% normal
horse serum for 1 hour. Endogenous biotin was blocked
by use of an avidin/biotin blocking kit (Vector Labora-
tories) then incubated overnight with primary antibody
(rabbit anti-a-smooth muscle actin 1:1000, Abcam; rab-
bit anti-von Willebrand factor 1:500, DakoCytomation;
rabbit anti-Mts1 1:2000, supplied by Dr N. Ambartsu-
mian; goat anti-rage 1:200, Abcam). Sections stained for
a-smooth muscle actin and Mts1 were then exposed (1
hour) to biotin-labeled anti-rabbit secondary antibodies
(Vector Laboratories) diluted 1:100, then to streptavidin-
biotin- horseradish peroxidase solution. Sections stained
for von willebrand factor and RAGE were exposed (1
hour) to horse radish peroxidase polymer secondary
antibody (Vector Laboratories). RAGE staining was
visualised using VIP peroxidise substrate kit (Vector)
and appeared as red colouration. This provides optimum
visualisation of RAGE staining in lung sections. Optimal
visualisation of all other antibodies was acheived using
3’,3’-diaminobenzidine tetrahydrochloride dihydrate and
hydrogen peroxide. For Mts1 staining, nickel enhance-
ment was used for optimizing contrast. Sections stained
for a-smooth muscle actin, von Willebrand factor and
Mts1 were counter-stained with haematoxylin. Eight
mice per group were studied.
Western blotting
Distal hPASMCs were supplied by Professor N. Morrell,
Department of Medicine, University of Cambridge
School of Clinical Medicine, UK [17]. hPASMCs were
grown in high glucose Dulbecco’s Modified Eagle Med-
ium (Invitrogen, UK) containing 10% foetal bovine
serum (Sera Laboratories International Ltd), and antibio-
tic, antimycotic solution (Sigma, UK). Cells were seeded
out in 6-well plates, and when approximately 80% con-
fluent, quiesced in 0.2% foetal bovine serum for 24
hours. Cells were then treated with 17b-estradiol (0.3-10
nM, Sigma, UK) for 4 hours, before being solubilised in
detergent lysis buffer and electrophoresed using the
NuPage system (Invitrogen, UK). Electrophoresed pro-
teins were transferred onto a PVDF membrane (Milli-
pore, UK), and blocked for an hour in 5% non-fat dried
milk in Tris-buffered saline with 0.2% tween. Primary
antibodies used were rabbit anti-Mts1 (1:1000) and
mouse anti-alpha tubulin (1:5000; Abcam UK). Primary
antibodies were applied overnight at 4°C, and blots thor-
oughly washed before addition of secondary antibody for
one hour at room temperature (goat anti-rabbit IgG,
1:1500, or rabbit anti-mouse IgG 1:5000; all from Sigma,
UK). All antibodies were diluted in 5% non-fat dried
milk. The blots were thoroughly washed and then incu-
bated with ECL reagent (Amersham Life Sciences, UK)
and exposed to film. The molecular weight marker See-
Blue plus 2 (Invitrogen, UK) was used to calibrate the
molecular weight range of the resolved proteins. After
probing with the relevant primary antibody, the mem-
brane was stripped and re-probed for the loading con-
trol alpha-tubulin. Densitometry was carried out using
TotalLab software (Nonlinear Dynamics, UK). The den-
sity of the Mts1 protein band was expressed as a ratio
of the density of the tubulin band. n = 6 experiments
were performed.
Proliferation of hPASMCs
hPASMCs were plated out in 24-well plates at a density
of 20,000 cells/well. After 24 hours cells were quiesced
in 0.2% foetal bovine serum for a further 24 hours. Cells
were then exposed to 2.5% foetal bovine serum in addi-
tion to 17b-estradiol (1 nM) in the presence or absence
of soluble RAGE (sRAGE, 2.5 μg/ml) for 5 days. sRAGE
can bind RAGE agonists, thus diverting the agonist
from the membrane bound form of the RAGE receptor
and antagonising RAGE. sRAGE was added at least 30
minutes prior to addition of 17b-estradiol. Fresh media
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counts were performed using a haemocytometer, and
counts from 4 experiments were repeated in duplicate.
Statistical analysis
Inter-group statistical com p a r i s o n sw e r em a d eb yo n e -
way analysis of variance with Dunnetts post test or two-
way analysis of variance with Bonferronis post test, as
appropriate. Data are expressed as mean ± SEM.
Results
Effects of gender on pulmonary vascular remodeling in
Mts1+ mice
Female Mts1+ mice exhibited an increase in pulmonary
vascular remodeling compared to female wildtype mice. In
contrast, male Mts1+ mice had no increase in pulmonary
vascular remodeling when compared against their respec-
tive wildtype controls (Figure 1A&1B). In addition, we also
observed that a subset of female Mts1+ mice (25%) exhib-
ited severe remodeling in a small number of resistance
arteries, which were characterized by neointimal formation
and virtual lumen occlusion. The existence of these oblit-
erative lesions was not observed in male Mts1+ mice (Fig-
ure 2A). Further examination of these lesions revealed that
they were similar to lesions previously described by Green-
way et al in a subset of Mts1+ mice (gender not documen-
ted) [6], and indicative of plexiform lesions observed in
human PAH. Extensive a-smooth muscle actin staining
was observed in the neointima of the plexiform-like
lesions (Figure 2B). Endothelial cells lining the obstructed
lumen of the pulmonary artery stained positive for von
Willebrand factor (Figure 2C). Both Mts1 (Figure 2D) and
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Figure 1 The effects of gender on pulmonary vascular remodeling in Mts1+ mice. A: Pulmonary vascular remodeling is increased in Mts1+
female mice compared to wildtype controls, but not in Mts1+ male mice (n = 4-6). Data are expressed as mean ± SEM and analysed by two-
way analysis of variance followed by Bonferronis post-test. ***P < 0.001 cf female wildtype & male Mts1+ mice. B: Representative images (x400
magnification) of resistance pulmonary arteries (stained with Elastica Van Gieson) observed in female wildtype, female Mts1+ mice, male
wildtype and male Mts1+ mice. Scale bars represent 50 μm.
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and advential layers of the plexiform-like lesions.
Effects of gender on sRVP and RVH in Mts1+ mice
Female Mts1+ mice displayed an elevation of systolic
right ventricular pressure (sRVP) compared with
wildtype controls (Figure 3A). In contrast, male Mts1+
mice did not develop increased sRVP compared to their
wildtype controls. Neither male nor female Mts1+ mice
exhibited an increase in RVH compared to their respec-
tive wildtype controls (Figure 3B).
B  C 
D  E 
Female Mts1+  Male Mts1+ 
A 
Figure 2 Plexiform-like lesions occur in female Mts1+ mice. A: Images of lung sections taken from female and male Mts1+ mice and stained
with a-smooth muscle actin (x200 magnification). A cluster of plexiform-like lesions can be seen in the female Mts1+ mouse, whereas
pulmonary arteries of a similar size in the male mouse show a much smaller smooth muscle cell layer and an intact lumen. Scale bars represent
100 μm. B-E: Representative images (x400 magnification) of plexiform-like lesions observed in female Mts1+ mice. Plexiform like lesions show
extensive a-smooth muscle actin staining in the neointimal layer (B). Staining with von-Willebrand factor shows endothelial cells lining the
obstructed lumen of the lesion (C). Mts1 (D) and RAGE (E) staining are evident in the endothelial and adventitial layers of the plexiform-like
lesions Scale bars represent 50 μm.
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mice
The effects of over-expression of Mts1 and gender were
selective for the pulmonary circulation, as neither mean
systemic arterial pressure (mSAP) nor heart rate were
affected (Table 1).
Effects of gender on expression of pulmonary Mts1 in
Mts1+ Mice
Having shown that Mts1+ female mice exhibit PAH
whilst Mts1+ male mice remain unaffected, we wished
to determine if differences in expression of Mts1
between male and female Mts1+ mice may contribute to
this phenotype in females. Our qRT-PCR results show
that, as expected, Mts1 mRNA was over-expressed in
the lungs of Mts 1+ mice, however this was more pro-
nounced in female mice than in males (Figure 4A). Mts
1 immuoreactivity appears localised to the medial and
adventitial layers of the distal pulmonary arteries, with
an exaggerated increase in Mts1 imminoreactivity in the
medial layer of pulmonary arteries of female Mts1+
mice (Figure 4B). As Mts1+ mice were created using the
HMGCoA reductase promoter we wished to rule out
gender differences in the expression of this promoter in
Mts1+ mice. We show equal expression of HMGCoA
reductase between male and female Mts1+ mice using
two housekeeping genes, b2- microglobulin and GAPDH
(Figure 4C).
Effects of gender on expression of pulmonary RAGE in
Mts1+ Mice
As Mts1 mediates its effects through interaction with
the RAGE receptor, we wished to assess if RAGE
expression also differed between male and female Mts1+
mice. Neither gender nor over-expression of Mts1 had
a n ye f f e c to nt h el e v e lo fR A G Eg e n ee x p r e s s i o ni nt h e
whole lung (Figure 5A). In line with this male and
female Mts1+ mice had similar patterns of RAGE
immunoreactivity in the distal pulmonary arteries (Fig-
ures 5B&5C). Although the data are not quantative,
immunoreactivity for RAGE appeared heightened in
lungs from both male and female Mts1+ mice compared
to wildtype controls (Figure 5B). RAGE appeared loca-
lised to the endothelial cell layer of small resistance pul-
monary arteries which were in proximity to airways
(Figure 5B). We also observed RAGE staining in Mts1+
mice in pulmonary arteries not associated with airways.
As the pattern of RAGE staining in these arteries was
different to the endothelial staining in the airway-asso-
ciated pulmonary arteries, we used a-smooth muscle
actin immunohistochemistry in subsequent lung sections
to localise RAGE staining. RAGE immunoreactivity
appeared localised to both the medial and adventitial
layers in non-airway associated pulmonary arteries from
both male and female Mts1+ mice (Figure 5C).
Interactions between 17b-estradiol and Mts1/RAGE in
hPASMCs
Having shown that female Mts1+ mice demonstrate
increased Mts1 and RAGE expression, we wished to
further investigate if this was likely mediated via 17b-
estradiol as we have previously shown this to be implicit
in the development of PAH in female mice overexpres-
sing the serotonin transporter (SERT) [18]. To translate
clinical relevance to our study, we adopted a human cell
model to assess these 17b-estradiol effects. 17b-estradiol
mediated a concentration-dependent increase in Mts1
expression in hPASMCs (Figure 6A). 17b-estradiol (1
nM) also stimulated proliferation of hPASMCs. This
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Figure 3 The effects of gender on sRVP and RVH in Mts1+
mice. A: sRVP is increased in Mts1+ female mice, but not in Mts1+
male mice (n = 5-9). B: RVH is unaffected in Mts1+ mice (n = 7-10).
***P < 0.001 cf wildtype controls. Data are expressed as mean ±
SEM and analysed by two-way analysis of variance followed by
Bonferronis post-test.
Table 1 The effects of gender and over-expression of
Mts1 on mean systemic arterial pressure (mSAP) and
heart rate (beats per minute, bpm) in mice
mSAP (mmHg) Heart Rate (bpm)
Wildtype female 99.5 ± 2.9 (6) 381 ± 11 (8)
Mts1+ female 92.7 ± 4.9 (8) 361 ± 10 (8)
Wildtype male 106.4 ± 4.9 (6) 383 ± 18 (6)
Mts1+ male 96.9 ± 5.4 (6) 384 ± 19 (6)
Data are expressed as mean ± SEM and analysed by two-way analysis of
variance followed by Bonferronis post-test. n shown in brackets. No statistical
significance was achieved.
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Figure 4 Mts1 expression is increased female Mts1+ mice compared to males. A: Mts1 gene expression is increased in the lungs of Mts1+
mice as assessed by qRT-PCR. This is exaggerated in lungs from female Mts1+ mice compared to male Mts1+ mice (n = 8). *P < 0.05 cf male
Mts1+ mice B: Representative images of pulmonary arteries (x400 magnification) from female wildtype mice, male wildtype mice, female Mts1+
mice and male Mts1+ mice stained for Mts1. Mts1 expression is localised to the medial and adventitial layers of non-plexiform like pulmonary
arteries and is most pronounced in female Mts1+ mice. Scale bars represent 20 μm. C: qRT-PCR analysis shows expression of the Mts1 promoter
HMGCoA reductase is not influenced by gender in Mts1+ mice. Both b2-microglobulin and GAPDH were used as endogenous controls.
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Figure 5 Expression of RAGE is similar between male and female Mts1+ mice. A: Whole lung RAGE gene expression is not affected by
either over-expression of RAGE or gender as assessed by qRT-PCR. B: Representative images of whole lung sections (x200 magnification) from
female wildtype mice, male wildtype mice, female Mts1+ mice and male Mts1+ mice stained for RAGE. RAGE immunoreactivity is localised to
the endothelial layer of pulmonary arteries adjacent to airways and is enhanced in both male and female Mts1+ mice compared to wildtype
controls. Red arrows point to pulmonary arteries. Scale bars represent 50 μm. B: Representative images of pulmonary arteries not adjacent to
airways (x400 magnification) showing RAGE and a-smooth muscle actin immunoreactivity on adjacent lung sections in male and female Mts1+
mice. RAGE appears to be expressed in the medial and adventitial layers of pulmonary arteries not adjacent to airways. Scale bars represent 20
μm.
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nist’ soluble RAGE (sRAGE; 2.5 μg/ml; Figure 6B).
Please note that it was not possible to generate sufficient
amounts of sRAGE to examine the in vivo effects in our
models.
Discussion
We have presented evidence that the Mts1/RAGE path-
way may play a role in the gender bias associated with
PAH. Female Mts1+ mice develop increased pulmonary
vascular remodeling and elevated right ventricular
pressure compared to male Mts1+ mice. A subset of
Mts1+ female mice (25%) also exhibit neointimal forma-
tion and lumen obliteration in a small number of pul-
monary resistance arteries, consistent with the
formation of plexiform-like lesions. These plexiform-like
lesions are not apparent in male Mts1+ mice. Develop-
ment of PAH and plexiform lesions have previously
been described in Mts1+ mice, however in these studies
there was no documentation of gender distribution and
cohorts were likely mixed [6,19]. This, therefore, is the
first study to show that the PAH phenotype in Mts1+
mice is specific to females. In accordance with Green-
w a ye ta l .[ 6 ]w es h o wt h a tp l e x i f o r m - l i k el e s i o n sa r e
observed only in a sub-group of Mts1+ mice, and that
these lesions are predominantly comprised of smooth
muscle cells in the neo-intimal layer with a thin layer of
endothelial cells lining the obliterated lumen. Also in
agreement with Greenway et al, we show Mts1 expres-
sion to be in the endothelial and adventitial layers of the
plexiform-like lesions. We further show that RAGE is
also expressed in the endothelial and adventitial layers
of the lesions in a similar pattern to Mts1. However,
there are also some discrepancies between the current
study and a previous study describing PAH in Mts1+
mice [19]. While we describe increased pulmonary vas-
cular remodeling in female Mts1+ mice, the Mts1+ mice
s t u d i e db yM e r k l i n g e re ta ls h o w e dn op u l m o n a r yv a s -
cular remodeling [19]. In addition, we did not observe
any differences in RVH in either male or female Mts1+
mice compared to controls. The original Mts1+ mice
studied by Merklinger et al. showed increased RVH [19],
but a later study by the same group showed Mts1+ mice
to have similar RVH to contr o lm i c e[ 2 0 ] .T h e r ea r e
three notable differences between our study and that of
Merklinger et al [19] which may contribute to the differ-
ent results obtained. Our study used mice at 5 months
of age whilst Merklinger et al. studied younger mice (~
2months of age). In addition, our study has separated
data from male and female mice whilst gender distribu-
tion was not described in the Merklinger et al. study
and cohorts were likely mixed. Finally, Merklinger et al
used C57BL6 mice as their wildtype controls while the
current study employed C57BL6 x CBA mice as wild-
type controls (Mts1+ mice are bred on a C57BL6 x
CBA background) [15]. The reasons we studied mice at
5 months of age were two-fold. Firstly, we have demon-
strated that the PAH phenotype does not present until 5
m o n t h so fa g ei ns o m et r a n s g e n i cm i c e ,f o re x a m p l ei n
mice over-expressing the serotonin transporter [21].
Secondly, female mice reach sexual maturity at 6-8
weeks of age, and can continue reproducing until
around 9-12 months old, although litter sizes will drop
around this time [22]. Thus at 5 months of age, female
mice are mid-late reproductive age which approximates
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Figure 6 Effects of 17b-estradiol on the Mts1/RAGE pathway in
hPASMCs. A:1 7 b-estradiol (0.3-10 nM) induces an increase in Mts1
protein in hPASMCs. Quantification of data from multiple
experiments (n = 4) is shown as mean ± SEM and analysed by one-
way ANOVA followed by Dunnetts post-test. *P < 0.05, **P < 0.01 vs
control. B:1 7 b-estradiol (1 nM) induced proliferation of hPASMCs is
inhibited in the presence of sRAGE (2.5 μg/ml). Data are shown as
mean ± SEM (n = 4) and analysed by one-way ANOVA followed by
Dunnetts post-test. **P < 0.01 vs 2.5% serum, ††P < 0.01 vs 1 nM
17b-estradiol.
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Page 9 of 12the age (average 35) in humans at which PAH presents
itself.
We show female Mts1+ mice to develop increased
sRVP despite a relatively small increase in pulmonary
vascular remodeling. This is in line with previous
reports describing increased sRVP in mice despite only
5-15% of vessels being remodeled [18,23]. Indeed, as dis-
cussed above, Merklinger et al showed increased sRVP
and RVH in Mts1+ mice despite these mice having simi-
lar levels of pulmonary vascular remodeling to wildtype
controls. Thus it is likely that factors additional to pul-
monary vascular remodeling contribute to increased pul-
monary pressures in mice. Indeed Mts1+ mice show
decreased lumen diameter of the left pulmonary artery,
and decreased attenuation of sRVP in response to nitric
oxide, suggesting elevated pulmonary vascular resistance
[7].
The dissociation between RVP and RVH observed in
female Mts1+ mice is consistent with previous observa-
tions using female mice at this age. For example, dex-
fenfluramine-dosed female mice develop increased RVP
in the absence of RVH, as do female mice over-expres-
sing the human SERT gene [18,21,23]. We and others
have shown that estrogen may have a protective effect
against RVH [18,24], and this may explain the dissocia-
tion between RVH and RVP we observe in the present
study.
Corresponding with the increased PAH phenotype
observed in female Mts1+ mice, Mts1 gene expression
was increased in the lungs of female Mts1+ mice com-
pared to male Mts1+ mice. Immunohistochemical analy-
s i ss h o w e di n c r e a s e dM t s 1p r o t e i ne x p r e s s i o ni nt h e
medial layer of small, resistance pulmonary arteries in
female compared to male Mts1+ mice. These gender
differences in Mts1 expression were not attributable to
gender influences on the expression of the HMGCoA
reductase promoter. Thus our results suggest an influ-
ence of sex hormones on Mts1 expression and subse-
quent PAH phenotype and we wished to assess the
effects of 17b-estradiol on Mts1 expression. To deter-
mine if our in vivo results in mice could be translated
to a human cell model, we chose to study hPASMCs. In
line with female Mts1+ mice showing increased expres-
sion of Mts1 in the medial layer of pulmonary arteries,
physiologically relevant concentrations of 17b-estradiol
up-regulated Mts1 expression in hPASMCs. Mts1 has
previously been shown to act in an autocrine fashion in
hPASMCs; it is released from and then acts upon these
cells to mediate proliferationa n dm i g r a t i o n[ 1 0 ] .T h u s
increased expression of Mts1 within the medial layer of
small resistance pulmonary arteries may contribute to
the increased remodeling observed in female Mts1+
mice. Mts1 exerts its effects on proliferation and migra-
tion in hPASMCs via RAGE [10]. Interestingly, we show
sRAGE to inhibit 17b-estradiol-induced proliferation of
hPASMCs. As Mts1 is the ligand for RAGE, collectively,
the results suggest that 17b-estradiol induces increased
expression of Mts1 that then activates RAGE and stimu-
lates hPASMC proliferation.
The mechanism by which Mts1 is released from
hPASMCs by serotonin involves co-operation between
the SERT and the 5-HT1B receptor [10]. In line with
this, Mts1 mRNA is up-regulated in the lungs of female
mice over-expressing SERT (SERT+ mice) [10]. We
have recently shown that female gender is permissive in
the development of PAH in SERT+ mice [18]. In addi-
tion we have shown a critical role for 17b-estradiol in
the development of PAH in female SERT+ mice as ovar-
iectomy reduces the PAH phenotype which can then be
re-established using subcutaneous 17b-estradiol
implants [18].
Previous studies have demonstrated that female gen-
der and/or estrogens can be protective in experimental
models of PAH, such as the hypoxic and monocrotaline
models and mice lacking the vasoactive intestinal pep-
tide gene [4,5,25]. This suggests that, in certain circum-
stances, female sex hormones may actually be protective
against PAH. Indeed, the estradiol metabolite 2-methox-
yestradiol (2-ME) has been shown to mediate protective
effects in monocrotaline induced PAH [26]. Estradiol is
metabolized to 2-hydroxyestradiol (2-OHE) mainly via
the estrogen metabolizing enzymes CYP1A1/2 and to a
lesser extent via CYP1B1. 2-OHE is then converted to
2-ME via catechol O-methyltransferase. Estradiol can
also be metabolized to 16a-hydroxyestrone (16-OHE1)
via various CYP enzymes including CYPs 1A1, 1A2 and
1B1 [27]. 2-OHE/2-ME may have anti-proliferative
effects on cells [26], while 16a-OHE1 stimulates cellular
proliferation by constitutively activating the estrogen
receptor [28]. Hence, both pro- and anti-proliferative
effects of estrogens may be observed, depending on
their metabolism. Consistent with this, both gene and
protein expression of CYP1B1 is increased in PASMCs
from PAH patients [29]. In addition, higher penetrance
of PAH is observed among BMPRII mutation carriers
with a polymorphism in the CYP1B1 genotype [30].
Interestingly, the 2-OHE/16a-OHE1 ratio was also
decreased in PAH patients with a BMPRII mutation
compared to unaffected BMPRII mutation carriers [30].
Disruption in the balance of estrogen metabolites may
therefore account for the differential effects of female
sex hormones in different models of PAH.
Conclusions
We have identified that female gender is permissive in
the development of PAH in 5 month old Mts1+ mice.
This may be related to increased Mts1 expression in
these females. 17b-estradiol can up-regulate Mts1
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Page 10 of 12expression and 17b-estradiol-induced proliferation of
hPASMCs is dependent upon RAGE activation. There-
fore the 17b-estradiol/Mts1/RAGE axis may play a role
in the development of PAH, and contribute to the gen-
der bias associated with this disease.
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